交易 Shionogi & Co., Ltd. - 4507 差價合約

交易條件

• 類型該金融市場可進行差價合約交易。了解更多：差價合約: 差價合約
• 點差: 6.3
• 長倉隔夜倉息調整長倉隔夜倉息調整保證金。您的投資¥1,000隔夜倉息來自頭寸全值的費用-0.013744 %(-¥3)使用杠杆的交易規模（大約值）¥20,000來自杠杆的資金 - 美元（大約值）¥19,000前往平台: -0.01374%
• 短倉隔夜倉息調整短倉隔夜倉息調整保證金。您的投資¥1,000隔夜倉息來自頭寸全值的費用-0.008478 %(-¥2)使用杠杆的交易規模（大約值）¥20,000來自杠杆的資金 - 美元（大約值）¥19,000前往平台: -0.00848%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: JPY
• 最低成交量: 1
• 保證金: 5.00%
• 證券交易所: Japan
• 交易佣金: 0%
• 保證止損溢價保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。: 1%

• 保證金。您的投資: ¥1,000
• 隔夜倉息來自頭寸全值的費用: -0.013744 %
  (-¥3)

• 保證金。您的投資: ¥1,000
• 隔夜倉息來自頭寸全值的費用: -0.008478 %
  (-¥2)

主要統計數據

• 前收盤價: 2932.2
• 開倉: 2927.5
• 1 年變化: -57.11%
• 日區間: 2911 - 2943.1

交易 Shionogi & Co., Ltd. - 4507

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company primarily focuses on metabolic syndrome, pain, infectious diseases, cholesterol medication, anti-hypertension drugs, depression treatment, prescription drugs, OTC drugs, and diagnostics. Its primary products include Cymbalta, a serotonin and noradrenaline reuptake inhibitor used for the treatment of depression, anxiety, diabetic neuropathic pain, fibromyalgia pain, chronic lower back pain, and osteoarthritis pain; Intuniv, a selective a2 adrenergic receptor agonist to treat attention-deficit hyperactivity disorder; Xofluza, an anti-influenza agent; and Symproic, a cancer pain analgesic tablet. It has a research collaborative agreement with National University Corporation Kyoto University to focus on drug discovery and medical research for the treatment of psychiatric disorders; strategic collaboration with Sage Therapeutics, Inc. to develop and commercialize SAGE-217 for MDD and other indications; license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics Inc.; a strategic collaboration with Tetra Discovery Partners LLC for the clinical development and commercialization of BPN14770, a selective phosphodiesterase-4D allosteric inhibitor; a collaborative research agreement with PeptiDream Inc. for the discovery and development of a series of blood brain barrier penetrating peptide drug-conjugate; and strategic alliance with Tetra Therapeutics to develop and commercialize BPN14770 for the treatment of Alzheimer's disease, Fragile X syndrome, and other indications. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.